Trial Profile
Safety and efficacy of adalimumab in patients with rheumatoid arthritis not adequately responding to standard antirheumatic therapies
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Jul 2017
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Acronyms STAR
- 17 Jun 2017 Results of post-hoc analysis presented at the 18th Annual Congress of the European League Against Rheumatism
- 05 Nov 2010 New trial record.